Faina Shtern, MD presented “Welcome and Opening Remarks” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
How to cite: Shtern, Faina “Welcome and Opening Remarks.” September 22, 2023. Accessed Nov 2024. https://grandroundsinurology.com/welcome-and-opening-remarks/
Welcome and Opening Remarks – Summary
Faina Shtern, MD, underscores the rapid progress in precision medicine. This approach, she notes, is revolutionizing prostate cancer diagnosis and treatment, leading to effective and personalized patient care.
In her remarks, Dr. Shtern reflects on the achievements and milestones reached in prostate cancer research and treatment. She acknowledges the contributions of the global medical community and the importance of interdisciplinary efforts in driving innovation and improving patient outcomes. She also highlights the ongoing challenges and areas where further research and development are needed to overcome obstacles in prostate cancer care.
She stresses the need for continued research and the integration of new technologies, such as artificial intelligence and advanced imaging techniques, to further enhance diagnostic accuracy and therapeutic outcomes.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Faina Shtern, MD, is the President and CEO of AdMeTech Foundation, a non-profit dedicated to ending the prostate cancer crisis. As a Founder of AdMeTech, Faina Shtern, MD, has been leading groundbreaking programs in prostate cancer research, education, awareness and advocacy, with a focus on the advancement of precision diagnostics and their integration with precision treatment, since 1997. This work has led to:
a) Development, global PI-RADS standardization, clinical evaluation, and implementation of precision MRI;
b) Establishment of molecular imaging, with priority focus on PSMA PET;
c) Original work in robotics for precision biopsy and treatment;
d) Recognition and expansion of radiogenomics; and
e) Precedent-setting legislation in US Congress and Massachusetts.
Prior to founding AdMeTech, Dr. Shtern served as Chief of the Diagnostic Imaging Research Branch at the National Cancer Institute, and Associate Director for Science and Technology, Office of Women’s Health, Office of the Secretary, US Department of Health and Human Services. She also led radiology research at Harvard Medical School’s Beth Israel Deaconess Medical Center and at Boston Children’s Hospital between 1999 and 2008.
Dr. Shtern has led and participated in numerous scientific and advisory committees, including the Breast Cancer Study Group of the National Academy of Medicine and Vice President Biden’s Cancer Moonshot Program. In 2016, she was named a “Woman of Influence” by the Boston Business Journal.
